Kemp Dolliver
Stock Analyst at Brookline Capital
(0.28)
# 4,047
Out of 4,831 analysts
17
Total ratings
25%
Success rate
-29.31%
Average return
Main Sectors:
Stocks Rated by Kemp Dolliver
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YMAB Y-mAbs Therapeutics | Initiates: Buy | $17 | $4.16 | +308.65% | 1 | Dec 5, 2024 | |
| EYEN Eyenovia | Downgrades: Hold | n/a | $1.15 | - | 2 | Nov 15, 2024 | |
| VRCA Verrica Pharmaceuticals | Downgrades: Hold | n/a | $0.55 | - | 2 | Oct 2, 2024 | |
| IBIO iBio, Inc. | Initiates: Buy | $3.6 | $0.80 | +350.00% | 1 | Jul 22, 2024 | |
| DARE Daré Bioscience | Upgrades: Buy | $36 | $2.89 | +1,145.67% | 2 | May 15, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $31 | $2.03 | +1,446.80% | 1 | Jan 25, 2024 | |
| CYCC Cyclacel Pharmaceuticals | Downgrades: Hold | n/a | $2.75 | - | 1 | Dec 19, 2023 | |
| LNTH Lantheus Holdings | Initiates: Buy | $100 | $78.95 | +26.66% | 1 | Nov 30, 2023 | |
| EDSA Edesa Biotech | Maintains: Buy | $57 | $2.00 | +2,750.00% | 2 | Oct 12, 2023 | |
| GNLX Genelux | Initiates: Hold | $25 | $2.48 | +908.06% | 1 | May 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.72 | +297.25% | 1 | Jan 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $8 | $0.97 | +728.84% | 1 | Oct 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $5.65 | $1.04 | +445.05% | 1 | Feb 2, 2022 |
Y-mAbs Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $17
Current: $4.16
Upside: +308.65%
Eyenovia
Nov 15, 2024
Downgrades: Hold
Price Target: n/a
Current: $1.15
Upside: -
Verrica Pharmaceuticals
Oct 2, 2024
Downgrades: Hold
Price Target: n/a
Current: $0.55
Upside: -
iBio, Inc.
Jul 22, 2024
Initiates: Buy
Price Target: $3.6
Current: $0.80
Upside: +350.00%
Daré Bioscience
May 15, 2024
Upgrades: Buy
Price Target: $36
Current: $2.89
Upside: +1,145.67%
Outlook Therapeutics
Jan 25, 2024
Upgrades: Buy
Price Target: $31
Current: $2.03
Upside: +1,446.80%
Cyclacel Pharmaceuticals
Dec 19, 2023
Downgrades: Hold
Price Target: n/a
Current: $2.75
Upside: -
Lantheus Holdings
Nov 30, 2023
Initiates: Buy
Price Target: $100
Current: $78.95
Upside: +26.66%
Edesa Biotech
Oct 12, 2023
Maintains: Buy
Price Target: $57
Current: $2.00
Upside: +2,750.00%
Genelux
May 18, 2023
Initiates: Hold
Price Target: $25
Current: $2.48
Upside: +908.06%
Jan 13, 2023
Initiates: Buy
Price Target: $19
Current: $4.72
Upside: +297.25%
Oct 21, 2022
Assumes: Buy
Price Target: $8
Current: $0.97
Upside: +728.84%
Feb 2, 2022
Initiates: Buy
Price Target: $5.65
Current: $1.04
Upside: +445.05%